2026-04-14T02:27:03Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4664452025-08-31T16:04:39Zcom_2072_98col_2072_378192

Prognostic factors in de novo metastatic renal cell carcinoma : A report from the latin american renal cancer group Abreu, Diego Carvalhal, Gustavo Gueglio, Guillermo Tobía González, Ignacio Pablo Garcia, Patricio Zuñiga, Alvaro Meza, Luis Bengió, Rúben Guillermo Scorticati, Carlos H. Castillejos, Ricardo Rodriguez, Francisco Autran Gómez, Ana María González Enguita, María del Carmen Gadú Campos-Salcedo, Jose Nolazco, Alejandro Ameri, Carlos Alberto Zampolli, Hamilton De Campos Langenhin, Raúl Muguruza, Diego Tobias-Machado, Marcos Mingote, Pablo Yandian, Juan Clavijo, Jorge Nogueira, Lucas Mendes Clark, Omar Secin, Fernando Rovegno, Agustín Roberto Vilas, Ana Barrios, Enrique Decia, Ricardo Cardoso Guimarães, Gustavo Glina, Sidney Pal, Sumanta K. Rodríguez, Óscar Palou, Juan Spiess, Philippe Lara, Primo Nery Marston Linehan, W. Pastore, Antonio Luigi Zequi, Stênio de Cássio Carcinoma, Renal Cell Humans Kidney Neoplasms Latin America Prognosis Treatment Outcome United States Altres ajuts: Janssen Biotech, Merck, Pharmacyclics, Incyte, Taiho Pharmaceutical. PURPOSE To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries. PATIENTS AND METHODS Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.5%) had metastasis at clinical presentation. Relationships between clinical and pathological parameters and treatment-related outcomes were analyzed by Cox regression and the log-rank method. RESULTS Of 530 patients, 184 (90.6%) had died of renal cell carcinoma. The median OS of the entire cohort was 24 months. American Society of Anesthesiology classification 3-4 (hazard ratio [HR]: 1.64), perirenal fat invasion (HR: 2.02), and ≥ 2 metastatic organ sites (HR: 2.19) were independent prognostic factors for 5-year OS in multivariable analyses. We created a risk group stratification with these variables: no adverse risk factors (favorable group), median OS not reached; one adverse factor (intermediate group), median OS 33 months (HR: 2.04); and two or three adverse factors (poor risk group), median OS 14 months (HR: 3.58). CONCLUSION Our study defines novel prognostic factors that are relevant to a Latin American cohort. With external validation, these easily discerned clinical variables can be used to offer prognostic information across low- and middle-income countries. 2021 Article de revisió https://ddd.uab.cat/record/272007 urn:10.1200/GO.20.00621 urn:oai:ddd.uab.cat:272007 urn:scopus_id:85105769181 urn:articleid:26878941v7p671 urn:pmid:33974442 urn:pmc-uid:8162501 urn:pmcid:PMC8162501 urn:oai:pubmedcentral.nih.gov:8162501 urn:oai:egreta.uab.cat:publications/f71f8753-c73c-468d-8266-773690ef39f6 eng JCO global oncology ; Vol. 7 (2021), p. 671-685 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. https://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf